Human iPS cell therapy for Spinal Cord Injury with Acronym: Human iPS in SCI
Our overall aim is to develop a clinically safe and effective neural cell therapy, combining novel biomaterials and human neural progenitor cells, to im...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NeuroStimSpinal
A STEP FORWARD TO SPINAL CORD INJURY REPAIR USING INNOVATIVE...
4M€
Cerrado
Piezo4Spine
Piezo-driven theramesh: A revolutionary multifaceted actuato...
4M€
Cerrado
SCINSCEF
Repair Spinal Cord Injury by Controlling Migration of Neural...
2M€
Cerrado
RTI2018-095872-B-C22
NUEVO DISPOSITIVO BIOACTIVO PARA LA REGENERACION DE LESIONES...
218K€
Cerrado
RTI2018-099908-B-C21
TERAPIAS DE REEMPLAZO NEURONAL EN DOS MODELOS ANIMALES DE DA...
109K€
Cerrado
PID2020-113480RB-I00
BIOIMPLANTES MAGNETICOS INTELIGENTES PARA REGENERACION NEURA...
218K€
Cerrado
Información proyecto HUMAN IPS IN SCI
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
195K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Human iPS cell therapy for Spinal Cord Injury with Acronym: Human iPS in SCI
Our overall aim is to develop a clinically safe and effective neural cell therapy, combining novel biomaterials and human neural progenitor cells, to improve functional outcome after spinal cord injury (SCI). We have the unique possibility to compare neuro-rescue potentials of human induced pluripotent stem (iPS) cells and their neural progeny, with that of human neural precursor cells from the already formed spinal cord.
The questions raised and studied in the present research program are unique with the introduction of human iPS cells and bioresorbable hydrogels. It offers future autologous transplantation procedures and thereby no immunological and reduced ethical considerations. If we manage, we can make patient-specific cell preparations to counteract the secondary degeneration after SCI. The project is of high relevance for clinical introduction of neural cell therapy after SCI, as well as other nervous system lesions.
Our proposed project will significantly contribute and add novel and multidisciplinary competencies to my profile as research fellow, developing my skills as a valid and independent European researcher. The cultural exchange with Karolinska Institutet will allow me to gain knowledge and skills in human neural stem cell, iPS techniques, SCI in vitro and in vivo models as well as in the field of biomaterial engineering. In addition, my genuine geographical move to Karolinska Institutet, Stockholm to perform this project, offers me to join, and add knowledge to, the European research community in developing effective future cell therapies for neurodegenerative and traumatic nervous system lesions.